Computational Drug Discovery
Read more
Making the Change of Drug Discovery
Formed in 2017, Novomol is a Germany-based life science start-up company focused on the continued advancement of our completely novel groundbreaking computational EDEN platform to discover new safe and efficacious drugs.
EDEN
The EDEN platform, developed by Hans-Joachim Boehm, is a completely novel computational approach to drug discovery. Using either 2D structures of active compounds or the 3D protein structures of the target as input, EDEN generates a complex affinity fingerprint.
September 2nd 2021
Novomol achieves positive validation for its in silico discovery engine EDEN
Novomol and OntoChem IT Solutions
Feel free to contact us for more information
contact@novomol.com